Neuropsychology in Neurodegenerative Diseases

A special issue of Brain Sciences (ISSN 2076-3425). This special issue belongs to the section "Neuropsychology".

Deadline for manuscript submissions: closed (1 March 2022) | Viewed by 5975

Special Issue Editor


E-Mail
Guest Editor
Department of Neurology, Medical University Innsbruck, 6020 Innsbruck, Austria
Interests: Parkinson's disease; impulse control disorders; decision making

Special Issue Information

Dear Colleagues,

This Special Issue invites original articles to update the knowledge on neuropsychology and neuropsychiatry in neurodegenerative diseases such as Parkinson’s disease, atypical Parkinson’s disease or Alzheimer’s disease. Studies that assess cognitive functions such as learning, memory, attention, information processing, theory of mind or emotional recognition as well as intervention studies aiming to improve neuropsychological or neuropsychiatric complications in neurodegenerative disease are welcome. We specifically encourage novel strategies which enable and may even facilitate cognitive assessment in patients with neurodegenerative disorders.  Studies that aim to shed light on the physiologic and metabolic mechanisms, such as oxidative stress and neuroinflammation or genetics in neurodegenerative diseases, are also welcome.

Research areas may include but are not limited to the following: experimental psychology, developmental psychology, neuropsychology, neuropsychiatry, movement disorders, functional brain imaging, and computer science.

I look forward to receiving your contributions.

Dr. Atbin Djamshidian
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neuropsychology
  • neuropsychiatry
  • cognition
  • impulsivity
  • decision making
  • information processing
  • functional brain imaging

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

8 pages, 554 KiB  
Article
Eye Tracking in Patients with Parkinson’s Disease Treated with Nabilone–Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Study
by Philipp Ellmerer, Marina Peball, Federico Carbone, Marcel Ritter, Beatrice Heim, Kathrin Marini, Dora Valent, Florian Krismer, Werner Poewe, Atbin Djamshidian and Klaus Seppi
Brain Sci. 2022, 12(5), 661; https://doi.org/10.3390/brainsci12050661 - 19 May 2022
Cited by 6 | Viewed by 2193
Abstract
The topic of the therapeutic use of cannabinoids in Parkinson’s disease (PD) is broadly discussed and frequently comes up in the outpatient clinic. So far, there are only a few randomized clinical trials assessing the effects of cannabinoids in PD. We are able [...] Read more.
The topic of the therapeutic use of cannabinoids in Parkinson’s disease (PD) is broadly discussed and frequently comes up in the outpatient clinic. So far, there are only a few randomized clinical trials assessing the effects of cannabinoids in PD. We are able to demonstrate a reduction in non-motor symptom (NMS) burden after the administration of nabilone. As impairment of attention and working memory have been described earlier as possible side effects, we assess cognitive performance using saccadic paradigms measured by an eye tracker. We do not observe a significant difference in any of the saccadic paradigms between PD patients on placebo versus those treated with nabilone. We, therefore, conclude that top-down inhibitory control is not affected by the tetrahydrocannabinol analogue. Nabilone did not significantly worsen cognitive performance and appears to be safe to use in selected PD patients who suffer from disabling NMS. Full article
(This article belongs to the Special Issue Neuropsychology in Neurodegenerative Diseases)
Show Figures

Figure 1

14 pages, 1260 KiB  
Article
Anatomically Standardized Detection of MRI Atrophy Patterns in Early-Stage Alzheimer’s Disease
by Lukas Lenhart, Stephan Seiler, Lukas Pirpamer, Georg Goebel, Thomas Potrusil, Michaela Wagner, Peter Dal Bianco, Gerhard Ransmayr, Reinhold Schmidt, Thomas Benke and Christoph Scherfler
Brain Sci. 2021, 11(11), 1491; https://doi.org/10.3390/brainsci11111491 - 11 Nov 2021
Cited by 4 | Viewed by 2951
Abstract
MRI studies have consistently identified atrophy patterns in Alzheimer’s disease (AD) through a whole-brain voxel-based analysis, but efforts to investigate morphometric profiles using anatomically standardized and automated whole-brain ROI analyses, performed at the individual subject space, are still lacking. In this study we [...] Read more.
MRI studies have consistently identified atrophy patterns in Alzheimer’s disease (AD) through a whole-brain voxel-based analysis, but efforts to investigate morphometric profiles using anatomically standardized and automated whole-brain ROI analyses, performed at the individual subject space, are still lacking. In this study we aimed (i) to utilize atlas-derived measurements of cortical thickness and subcortical volumes, including of the hippocampal subfields, to identify atrophy patterns in early-stage AD, and (ii) to compare cognitive profiles at baseline and during a one-year follow-up of those previously identified morphometric AD subtypes to predict disease progression. Through a prospectively recruited multi-center study, conducted at four Austrian sites, 120 patients were included with probable AD, a disease onset beyond 60 years and a clinical dementia rating of ≤1. Morphometric measures of T1-weighted images were obtained using FreeSurfer. A principal component and subsequent cluster analysis identified four morphometric subtypes, including (i) hippocampal predominant (30.8%), (ii) hippocampal-temporo-parietal (29.2%), (iii) parieto-temporal (hippocampal sparing, 20.8%) and (iv) hippocampal-temporal (19.2%) atrophy patterns that were associated with phenotypes differing predominately in the presentation and progression of verbal memory and visuospatial impairments. These morphologically distinct subtypes are based on standardized brain regions, which are anatomically defined and freely accessible so as to validate its diagnostic accuracy and enhance the prediction of disease progression. Full article
(This article belongs to the Special Issue Neuropsychology in Neurodegenerative Diseases)
Show Figures

Figure 1

Back to TopTop